Fourth-generation Epidermal Growth Factor Receptor-tyrosine Kinases Inhibitors: Hope and Challenges

Overview

Journal Transl Cancer Res

Specialty Oncology

Date 2024 Sep 12

PMID 39262457

Authors

Chunxia Su

Shi-Yong Sun

Affiliations

Soon will be listed here.

References

Lu X, Zhang T, Zhu S, Xun Q, Tong L, Hu X . Discovery of JND3229 as a New EGFR Mutant Inhibitor with In Vivo Monodrug Efficacy. ACS Med Chem Lett. 2018; 9(11):1123-1127. PMC: 6231186. DOI: 10.1021/acsmedchemlett.8b00373. View

To C, Jang J, Chen T, Park E, Mushajiang M, De Clercq D . Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor. Cancer Discov. 2019; 9(7):926-943. PMC: 6664433. DOI: 10.1158/2159-8290.CD-18-0903. View

Engelhardt H, Bose D, Petronczki M, Scharn D, Bader G, Baum A . Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors. J Med Chem. 2019; 62(22):10272-10293. DOI: 10.1021/acs.jmedchem.9b01169. View

Lu X, Yu L, Zhang Z, Ren X, Smaill J, Ding K . Targeting EGFR and EGFR resistance mutations in NSCLC: Current developments in medicinal chemistry. Med Res Rev. 2018; 38(5):1550-1581. DOI: 10.1002/med.21488. View

Lee D . Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures. Pharmacol Ther. 2017; 174:1-21. DOI: 10.1016/j.pharmthera.2017.02.001. View

da Cunha Santos G, Shepherd F, Tsao M . EGFR mutations and lung cancer. Annu Rev Pathol. 2010; 6:49-69. DOI: 10.1146/annurev-pathol-011110-130206. View

Jia Y, Yun C, Park E, Ercan D, Manuia M, Juarez J . Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors. Nature. 2016; 534(7605):129-32. PMC: 4929832. DOI: 10.1038/nature17960. View

Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M . Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer. 2019; 121(9):725-737. PMC: 6889286. DOI: 10.1038/s41416-019-0573-8. View

Lim S, Fujino T, Kim C, Lee G, Lee Y, Kim D . BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non-Small Cell Lung Cancer. Clin Cancer Res. 2023; 29(16):3004-3016. PMC: 10425724. DOI: 10.1158/1078-0432.CCR-22-3901. View

10.

Eno M, Brubaker J, Campbell J, De Savi C, Guzi T, Williams B . Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer. J Med Chem. 2022; 65(14):9662-9677. PMC: 9340769. DOI: 10.1021/acs.jmedchem.2c00704. View

11.

Ramalingam S, Vansteenkiste J, Planchard D, Cho B, Gray J, Ohe Y . Overall Survival with Osimertinib in Untreated, -Mutated Advanced NSCLC. N Engl J Med. 2019; 382(1):41-50. DOI: 10.1056/NEJMoa1913662. View

12.

Liu Y, Lai M, Li S, Wang Y, Feng F, Zhang T . LS-106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo. Cancer Sci. 2021; 113(2):709-720. PMC: 8819286. DOI: 10.1111/cas.15229. View

13.

To C, Beyett T, Jang J, Feng W, Bahcall M, Haikala H . An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer. Nat Cancer. 2022; 3(4):402-417. PMC: 9248923. DOI: 10.1038/s43018-022-00351-8. View